NCT06336239 PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study
| NCT ID | NCT06336239 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Anzhen Hospital |
| Condition | Cardiovascular Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-12-21 |
| Primary Completion | 2024-07-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2023-12-21 with a primary completion date of 2024-07-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The association between Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) is well established. Traditional risk factors for CVD and CKD are similar, with type 2 diabetes mellitus (T2DM) being the most prevalent risk factor. However, CKD is underdiagnosed and undertreated in patients with CVD. Further understanding of the combination of CKD in CVD patients is important to formulate prevention and treatment strategies for CVD patients and high-risk groups, reduce adverse events in CVD patients, and prevent progression of CKD to End Stage Renal Disease (ESRD).
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years old; * Diagnosed T2DM combined with ≥1 CVD (hypertension, coronary heart disease, atrial fibrillation, heart failure); * During the data collection period, they went to the outpatient clinic of the cardiology department of the research center, or received treatment in the cardiology department; * Ability to self-sign informed consent (electronic /paper). Exclusion Criteria: * Pregnant or lactating women; * Dialysis patients; * Other diseases that lead to elevated albuminuria, such as severe infection, confirmed primary glomerular disease, etc.; . Malignant tumors being treated (surgery, chemotherapy, radiotherapy or targeted therapy); * Cachexia (CSS score ≥ 5 points); * Severe liver disease (Child- Pugh grade C) ; * Participated in an interventional clinical trial in the past three months.
Contact & Investigator
Changsheng Ma, Doctor
PRINCIPAL INVESTIGATOR
Beijing Anzhen Hospital
Frequently Asked Questions
Who can join the NCT06336239 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06336239 currently recruiting?
Yes, NCT06336239 is actively recruiting participants. Contact the research team at duxinheart@sina.com for enrollment information.
Where is the NCT06336239 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Chongqing, China and 11 additional locations.
Who is sponsoring the NCT06336239 clinical trial?
NCT06336239 is sponsored by Beijing Anzhen Hospital. The principal investigator is Changsheng Ma, Doctor at Beijing Anzhen Hospital. The trial plans to enroll 3,000 participants.